Research Article
The Effects of the KCNQ Openers Retigabine and Flupirtine on Myotonia in Mammalian Skeletal Muscle Induced by a Chloride Channel Blocker

Tzu-Rong Su,1 Wen-Shan Zei,2 Ching-Chyuan Su,1 George Hsiao,3 and Min-Jon Lin2,4

1 Tian-Sheng Memorial Hospital, Tong-Kang, Pintong, Taiwan
2 School of Biomedical Sciences, Chung Shan Medical University, Taichung 402, Taiwan
3 Department and Graduate Institute of Pharmacology, College of Medicine, Taipei Medical University, Taipei, Taiwan
4 Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan

Correspondence should be addressed to Min-Jon Lin, mjl@csmu.edu.tw

Received 2 December 2011; Accepted 12 January 2012

Academic Editor: Ke Ren

Copyright © 2012 Tzu-Rong Su et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The purpose of this study was to investigate the effect of KCNQ (potassium channel, voltage-gated, KQT-like subfamily) openers in preventing myotonia caused by anthracene-9-carboxylic acid (9-AC, a chloride channel blocker). An animal model of myotonia can be elicited in murine skeletal muscle by 9-AC treatment. KCNQ openers, such as retigabine and flupirtine, can inhibit the increased twitch amplitude (0.1 Hz stimulation) and reduce the tetanic fade (20 Hz stimulations) observed in the presence of 9-AC. Furthermore, the prolonged twitch duration of skeletal muscle was also inhibited by retigabine or flupirtine. Lamotrigine (an anticonvulsant drug) has a lesser effect on the muscle twitch amplitude, tetanic fade, and prolonged twitch duration as compared with KCNQ openers. In experiments using intracellular recordings, retigabine and flupirtine clearly reduced the firing frequencies of repetitive action potentials induced by 9-AC. These data suggested that KCNQ openers prevent the myotonia induced by 9-AC, at least partly through enhancing potassium conductance in skeletal muscle. Taken together, these results indicate that KCNQ openers are potential alternative therapeutic agents for the treatment of myotonia.

1. Introduction

KCNQ (potassium channel, voltage-gated, KQT-like subfamily) potassium channels (Kv7) play a major role in controlling membrane excitability and thus represent interesting drug targets for the treatment of epilepsy and neuropathic pain [1–3]. To date, in mammals, five members of the KCNQ family have been reported [1]: Kv7.1 to Kv7.5. These are potassium (K⁺) channel proteins that are widely distributed in the brain, inner ear, heart, pancreas, lung, and placenta [4–8]. Retigabine and flupirtine, voltage-dependent KCNQ K⁺ channel (Kv7) openers, exert anticonvulsant and analgesic actions in the central nervous system [9–11]. Retigabine also has antinociceptive effects in rat models of persistent and chronic pain. The antinociceptive effects associated with retigabine administration were reversed by coadministration of KCNQ blockers [10–13]. Flupirtine, a compound that is structurally similar to retigabine, enhances the activation of KCNQ K⁺ channels. This drug can prevent and suppress seizures in both the kainic acid and fluoroethyl models of symptomatic neonatal seizures [14] and is a centrally-acting, nonopioid analgesic that may prove useful in the treatment of a variety of pain states [15]. In addition to anticonvulsant and analgesic effects, several studies have shown that retigabine and flupirtine exert neuroprotective effects on central neurons [16–20]. Recent studies have reported that Kv7.1 [21] and Kv7.5 [22, 23] transcripts are expressed in adult skeletal muscle. Transcript levels of Kv7.1 and Kv7.5 are increased during in vitro proliferation and differentiation of rat myoblasts [24]. More recently, Iannotti et al. [25] showed that Kv7 K⁺ channels are expressed in differentiating C2C12 cells and myotubes [25]. However, the functional role of KCNQ K⁺ channels in mammalian skeletal muscle remains unknown. K⁺ channels may play a role in the patterns of muscle contraction and relaxation and potentially modulate the resting membrane potential.
2 Evidence-Based Complementary and Alternative Medicine

Figure 1: Effects of retigabine and flupirtine on the anthracene-9-carboxylic-acid (9-AC)-induced myotonia. Representative muscle contraction traces recorded from mouse phrenic nerve-diaphragm preparations are shown in (a)–(c). The addition of 9-AC (0.1 mM) increased the amplitude of muscle contractions. Treatment with retigabine (0.03 mM, (a)) and flupirtine (0.03 mM, (b)) resulted in an inhibition of the increased amplitude of muscle contractions induced by 9-AC. Lamotrigine (0.03 mM) has no inhibitory effect on the muscle amplitude induced by 9-AC (c). (d) Dose-response effects of retigabine, flupirtine, and lamotrigine on 9-AC-induced myotonia. Percent of control (y-axis): the twitch amplitude ratio of after treatment (retigabine, flupirtine, or lamotrigine) to before treatment (9-AC alone).

of skeletal muscle cells [26]. In addition to K⁺ channels, chloride (Cl⁻) conductance accounts for more than 70% of the resting conductance in mammalian skeletal muscle. Myotonia occurs naturally in several species (humans, goats, mice) as a result of a genetic deficiency in the skeletal muscle CLC-1 Cl⁻ channel, a disease termed myotonia congenita in humans [27–30]. An animal model of myotonia in mammalian skeletal muscle can be induced by treatment with the Cl⁻ channel blocker 9-anthracene carboxylic acid. In the present studies, the effects of KCNQ K⁺ openers on Cl⁻ channel blocker-induced myotonia were investigated. It was found that KCNQ K⁺ openers but not lamotrigine (an anticonvulsant drug with no effect on KCNQ channel activity) inhibited muscle myotonia and the firing frequency of repetitive action potentials induced by the Cl⁻ channel blocker.

2. Materials and Methods

2.1. Mouse Phrenic Nerve-Diaphragm Preparations. ICR strain mice (17–22 g) were sacrificed inhaled carbon dioxide. Phrenic nerve-diaphragm preparations were isolated and suspended in an organ bath containing 10 mL modified Krebs’ solution at 36 ± 1°C and oxygenated with carbogen (95% O₂ + 5% CO₂). The composition of the modified Krebs’ solution was the following (in mM): NaCl (131), KCl
Figure 2: The effects of retigabine, flupirtine and lamotrigine on the statistical time-course curves of indirect-(nerve) and direct-(muscle) stimulated muscle contractions induced by 9-AC (0.01 mM). (a)–(c) and (d)–(f) are the muscle tensions elicited by indirect and direct stimulation at 0.1 Hz, respectively. Retigabine (0.03 mM, (a, d)) and flupirtine (0.03 mM, (b, e)), but not lamotrigine (0.03 mM, (c, f)), significantly inhibited the 9-AC-induced increase in muscle amplitude. 9-AC was applied at time zero. Retigabine, flupirtine, or lamotrigine was applied at time 15 min. $^*P<0.01$ as compared with 9-AC treatment alone. Control: no chemical treatment.
Figure 3: The effects of retigabine, flupirtine, and lamotrigine on the duration of isometric twitches induced by 9-AC (0.1 mM). The representative traces of muscle twitches showed the effects of retigabine (0.03 mM, (a)), flupirtine (0.03 mM, (b)), and lamotrigine (0.03 mM, (c)) on the prolonged duration of muscle twitches induced by 9-AC. Retigabine and flupirtine shortened the duration of muscle twitches in the presence of 9-AC. Linopirdine (0.05 mM), a KCNQ blocker, antagonises the effects of retigabine and flupirtine on the duration of muscle twitches. * a high-resolution time scale: 200 msec.

Figure 4: Statistical bar graph of the effects of KCNQ openers, lamotrigine and linopirdine (0.05 mM) on the twitch duration (TD50) of the muscle induced by 9-AC (0.1 mM). Control: no chemical treatment; 9-AC: 9-AC treatment alone; Ret: retigabine (0.03 mM); Flu: flupirtine (0.03 mM); Flu-lino: flupirtine plus linopirdine; Lam: lamotrigine; Lam-lino: lamotrigine plus linopirdine. TD50: twitch duration at 50% of the amplitude. * P < 0.05 as compared with 9-AC alone; * P < 0.01 as compared with retigabine (ret) or flupirtine (flu); N.S: no significance.

and had impedances between 10–15 MΩ. Single or multiple action potentials were evoked by intracellular injection of depolarising current pulses (20 nA; 200 ms). The signals of membrane potentials and action potentials were digitised at 20–100 kHz and stored using DigiData 1322 A (Axon Instruments). Data were analysed using the pClamp 9.0 software (Axon Instruments).

2.3. Drugs and Chemicals. Retigabine was purchased from LKT laboratories (USA). Flupirtine, and lamotrigine were purchased from Tocris Bioscience, Inc. (UK). D-tubocurarine was purchased from Fluka Inc. (USA). Retigabine, Flupirtine and lamotrigine were dissolved in dimethyl sulfoxide (DMSO); d-tubocurarine was dissolved in distilled water.
2.4. Statistics. The data are provided as the mean ± S.E.M. Statistically significant of differences were evaluated using a paired or unpaired Student’s t-test. When more than one group was compared with one control, significance was evaluated using one-way analysis of variance (ANOVA). Probability values (P) less than 0.01 were considered significant.

3. Results

3.1. Effects of KCNQ Openers on the Muscle Contractions Induced by Anthracene-9-Carboxylic Acid (9-AC). 9-AC, a potent myotonia inducer, can cause increased membrane excitability and slowed muscle relaxation. The application of 9-AC (0.1 mM) caused an increase in twitch amplitude under direct stimulation conditions at a frequency of 0.1 Hz (Figure 1). Treatment with retigabine (Ret; Figure 1(a)), and flupirtine (Flu; Figure 1(b)) but not lamotrigine (Lam; Figure 1(c)) significantly inhibited the increased amplitude of muscle contraction induced by 9-AC. Figure 1(d) shows the dose-response relationship of KCNQ openers and lamotrigine. Figure 2 shows the time course of muscle force responses to indirect (Figures 2(a)–2(c)) and direct (Figures 2(d)–2(f)) stimulation. The effects of retigabine and flupirtine on the response of 9-AC-treated muscle are similar in both indirect (via nerve) and direct (via muscle) stimulation. The maximal twitch amplitudes induced by 9-AC from three independent experiments groups were 188.3 ± 28.4, 166.2 ± 6.0, and 192.4 ± 9.6% of the control. Treatment with the KCNQ openers retigabine (Figures 2(a) and 2(d)) and flupirtine (Figures 2(b) and 2(e)), but not the anticonvulsant drug lamotrigine (182.4 ± 10.1%; Figures 1(c) and 2(f)), significantly inhibited the twitch amplitude induced by 9-AC (indirect stimulation: from 167.7 ± 15.8 to 91.1 ± 9.2% for Ret and 176.1 ± 20.7 to 119.9 ± 9.7% for Flu; direct stimulation: from 188.3 ± 28.4 to 104.4 ± 6.9% for Ret and 166.2 ± 6.0 to 115.65 ± 3.5% for Flu). The prolongation of the relaxation period in skeletal muscle induced by 9-AC (TD50: 386.6 ± 50.1 ms) is also significantly inhibited by treatment with retigabine (31.3 ± 1.9 ms) and flupirtine (29.3 ± 3.2 ms) (Figures 3 and 4). Linopirdine (Lino), a KCNQ blocker, reversed the effects of retigabine and flupirtine on the twitch duration (TD50) induced by 9-AC (Ret + Lino: 167.1 ± 19.5 ms; Flu + Lino: 155.0 ± 40.3 ms). Lamotrigine inhibits...
the prolonged relaxation period induced by 9-AC to a lesser extent than retigabine or flupirtine do (Figure 4). However, linopirdine cannot reverse the effects of lamotrigine on the inhibition of twitch duration induced by 9-AC (Figure 4).

3.2. Effects of KCNQ Openers on the Muscle Contractions Induced by 9-AC at 20 Hz Stimulation. In the skeletal muscle without any chemical treatment, the typical tetanic contraction maintenance (TCM) index by direct and indirect stimulation at 20 Hz ranged from 1.28–1.47 (1.31 ± 0.03 for indirect stimulation, n = 18; 1.43 ± 0.08 for direct stimulation; Figures 5(a)–5(f)). The application of 9-AC caused a fade of tetanic contractions (muscle unable to sustain a contraction continuously) both in response to indirect (Figures 5(a)–5(c)) and direct (Figures 5(d)–5(f)) stimulation at 20 Hz (TCM index: 0.53 ± 0.04 for indirect stimulation, n = 21; 0.51 ± 0.05 for indirect stimulation, n = 21). Treatment with retigabine and flupirtine, but not lamotrigine, can reverse the fade of tetanic contractions induced by 9-AC. The TCM index values of 9-AC-treated diaphragm increase from 0.50 ± 0.04 to 1.34 ± 0.09 for indirect stimulation and 0.49 ± 0.03 to 1.33 ± 0.05 for direct stimulation after retigabine treatment; additionally, flupirtine treatment increases TCM index values from 0.50 ± 0.03 to 0.99 ± 0.09 for indirect stimulation and 0.50 ± 0.03 to 1.14 ± 0.05 for direct stimulation (Figure 5). Treatment with lamotrigine cannot reverse the TCM index values of 9-AC-treated diaphragms, which were observed as 0.60 ± 0.04 to 0.36 ± 0.05 for indirect stimulation and 0.55 ± 0.09 to 0.34 ± 0.04 for direct stimulation.

3.3. Effects of KCNQ Openers on the Frequency of Action Potentials Induced by 9-AC. The mean frequencies of action potentials of sarcolemma evoked by a depolarisation square pulse stimulation (20 nA, 0.2 sec) without any chemical treatment are 1.27 ± 0.13, 1.53 ± 0.18, and 1.55 ± 0.31 Hz in the three experimental groups, respectively (Figures 6(a)–6(c): control). The application of 9-AC (0.1 mM) to skeletal muscle fibres increased the firing frequency of repetitive action potentials (38.7 ± 1.9, 32.7 ± 1.8 and 32.4 ± 1.3 Hz in the three experimental groups, resp.) (Figures 6(a)–6(c): 9-AC). Retigabine (Figure 6(a)) and Flupirtine (Figure 6(b)), but not lamotrigine (Figure 6(c)), significantly inhibit the firing frequency of action potentials induced by 9-AC (retigabine: 9-AC+Ret 30 µM, 9-AC+Flu 30 µM, and 9-AC+Lam 30 µM, respectively).

Figure 6: The effects of retigabine, flupirtine, and lamotrigine on the firing frequency of repetitive action potentials induced by 9-AC (0.1 mM). A train of muscle action potentials was triggered by a depolarising current injection (20 nA, 200 msec) through the recording pipette. The effects of retigabine (0.03 mM), flupirtine (0.03 mM), and lamotrigine (0.03 mM) on the firing frequency of action potentials induced by 9-AC are shown in (a, b, and c), respectively. ∗P < 0.01 as compared with 9-AC alone.
Figure 7: The effects of retigabine, flupirtine, and lamotrigine on the maximum rise slope of action potentials. The effects of retigabine (0.03 mM), flupirtine (0.03 mM), and lamotrigine (0.03 mM) on the maximum rise slope of action potentials are shown in (a, b, and c), respectively. *P < 0.01 as compared with before the chemical treatment.

from 38.7 ± 1.9 to 7.5 ± 0.9 Hz; flupirtine: from 32.7 ± 1.8 to 10.5 ± 0.8 Hz; lamotrigine: from 32.4 ± 1.3 to 27.0 ± 1.7 Hz).

3.4. Effects of KCNQ Openers on Rise of the Slope of the Action Potential. To determine whether KCNQ4 openers affect the sodium channel, the maximum rise slopes of action potentials were measured. The results showed that retigabine and flupirtine are unable to affect the maximum rise slope of action potentials (427.1 ± 10.1 mV/ms and 386.3 ± 19.8 mV/ms, before and after treatment with retigabine, resp.; 427.6 ± 29.1 mV/ms and 395.9 ± 20.1 mV/ms, before and after treatment with flupirtine, resp.) (Figure 7). Lamotrigine slightly but significantly inhibits the maximum rise slope of action potentials (440.9 ± 21.0 and 345.4 ± 21.8 mV/ms, before and after treatment with lamotrigine, resp.) (Figure 7).

4. Discussion

Mutations in the CLCN1 gene cause membrane hyperexcitability in skeletal muscle. The resulting transient muscle stiffness is characterised by involuntary aftercontractions and a slowed relaxation (myotonia). This condition can also be recapitulated experimentally by blocking membrane chloride (Cl\(^{-}\)) channels of normal muscle with 9-anthracene carboxylic acid (9-AC) [29, 31–33]. 9-AC causes the repetitive firing of action potentials in mammalian skeletal muscle membranes and thus induces slowed relaxation in skeletal muscle. We applied 9-AC (0.1 mM) to mouse skeletal muscle to produce an animal model of myotonia. In the present study, we compared the effects of retigabine, flupirtine, and lamotrigine on 9-AC-induced myotonia in mouse skeletal muscle. Our results showed that retigabine and flupirtine, but not lamotrigine, can significantly reduce the myotonic membrane hyperexcitability induced by 9-AC. Because retigabine and flupirtine did not cause changes in the rise slope of the action potentials, the effects of retigabine and flupirtine were not similar with sodium (Na\(^{+}\)) channel blockers. It has been reported that retigabine is a selective Kv7 (KCNQ) potassium channel opener [34–36], which can act as an anticonvulsant by reducing excitability through the stabilisation of the neuronal membrane. Flupirtine also
acts as a Kv7 channel opener and is a centrally acting, nonopioid analgesic with muscle relaxant properties that is advocated for use in a number of pain conditions [37]. Confocal immunoblotting analysis of the mammalian skeletal sarcolemma demonstrated the distribution of Kv7 2 and Kv7 3 to be in Z-line and Kv7 4 expression to be restricted to the plasma membrane [25]. From these data, it appeared that KCNQ proteins existed on the plasma membranes of skeletal muscle. However, it is not known whether the KCNQ openers can effectively reduce the membrane overexcitability of mammalian skeletal muscle. In this experiment, we demonstrated that flupirtine, and retigabine can inhibit the membrane excitability of skeletal muscle induced by 9-AC, and these effects can be reversed by treatment with the KCNQ blocker linopirdine. Lamotrigine, a Na+ blocker in the central nervous system that acts without treatment with the KCNQ blocker linopirdine. Lamotrigine, muscle induced by 9-AC, and these e

In this experiment, we demonstrated that flupirtine, and retigabine, the drug of choice for reducing myotonia of excitability induced by 9-AC. Therefore, flupirtine and retigabine inhibit membrane excitability induced by 9-AC through effects on the KCNQ channel rather than on the blockade of the Na+ channel. In clinical practice, various Na+ channel blockers have been used to treat myotonia, such as carbamazepine, mexiletine, phenytoin, and procainamide. Mexiletine is the drug of choice for reducing myotonia in myotonic dystrophy type I [38]. Na+ channel blockers have some unwanted effects, including a tendency to reduce muscle force by decreasing muscle action potentials. A

A-channel opener is not currently available for our use; therefore, we are utilising Na+ channel blockers to treat myotonia. Although lamotrigine has been shown to act at voltage-sensitive Na+ channels and stabilise neural membranes, it has a lesser effect on muscle myotonia as compared with KCNQ openers (e.g., retigabine and flupirtine). The effect of lamotrigine may be more selective in the central nervous system than in peripheral tissues. Evidence from this study suggests that KCNQ openers may be a new class of drugs for the treatment of myotonia. Because retigabine and flupirtine cannot significantly change the rise slope of action potentials, the unwanted effects on Na+ channels can thus be excluded. All of these studies indicate that retigabine and flupirtine may be considered useful in the treatment of myotonia.

Acknowledgments

This work was supported by Grants from the National Science Council of Taiwan (NSC 100-2320-B-040-001) and Chung Shan Medical University (CSMU-100-OM-A-017).

References

[1] C. C. Shieh, M. Coghlan, J. P. Sullivan, and M. Gopalakrishnan, “Potassium channels: molecular defects, diseases, and therapeutic opportunities,” Pharmacological Reviews, vol. 52, no. 4, pp. 557–593, 2000.

[2] Y. J. Wu and S. I. Dworetzky, “Recent developments on KCNQ potassium channel openers,” Current Medicinal Chemistry, vol. 12, no. 4, pp. 453–460, 2005.

[3] D. A. Brown and G. M. Passmore, “Neural KCNQ (Kv7) channels,” British Journal of Pharmacology, vol. 156, no. 8, pp. 1185–1195, 2009.

[4] Q. Wang, M. E. Curran, I. Splawski et al., “Positional cloning of a novel potassium channel gene: KCVQT1 mutations cause cardiac arrhythmias,” Nature Genetics, vol. 12, no. 1, pp. 17–23, 1996.

[5] N. A. Singh, C. Charlier, D. Stauffer et al., “A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns,” Nature Genetics, vol. 18, no. 1, pp. 25–29, 1998.

[6] C. Kubisch, B. C. Schroeder, T. Friedrich et al., “KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness,” Cell, vol. 96, no. 3, pp. 437–446, 1999.

[7] J. Robbins, “KCNQ potassium channels: physiology, pathophysiology, and pharmacology,” Pharmacology and Therapeutics, vol. 90, no. 1, pp. 1–19, 2001.

[8] I. A. Greenwood and S. Ohya, “New tricks for old dogs: KCNQ expression and role in smooth muscle,” British Journal of Pharmacology, vol. 156, no. 8, pp. 1196–1203, 2009.

[9] A. Rostock, C. Tober, C. Rundfeldt et al., “D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures,” Epilepsy Research, vol. 23, no. 3, pp. 211–223, 1996.

[10] G. Blackburn-Munro and B. S. Jensen, “The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain,” European Journal of Pharmacology, vol. 460, no. 2–3, pp. 109–116, 2003.

[11] M. P. G. Korsgaard, B. P. Hartz, W. D. Brown, P. K. Ahring, D. Stroback, and N. R. Mirza, “Anxiolytic effects of maxipox (BMS-204352) and retigabine via activation of neuronal Kv7 channels,” Journal of Pharmacology and Experimental Therapeutics, vol. 314, no. 1, pp. 282–292, 2005.

[12] C. Roza and J. A. Lopez-Garcia, “Retigabine, the specific KCNQ channel opener, blocks ectopic discharges in axotomized sensory fibres,” Pain, vol. 138, no. 3, pp. 537–545, 2008.

[13] P. M. Lang, J. Fleckenstein, G. M. Passmore, D. A. Brown, and P. Grafe, “Retigabine reduces the excitability of unmethylated peripheral human axons,” Neuropharmacology, vol. 54, no. 8, pp. 1271–1278, 2008.

[14] Y. H. Raol, D. A. Lapides, J. G. Keating, A. R. Brooks-Kayal, and E. C. Cooper, “A KCNQ channel opener for experimental neonatal seizures and status epilepticus,” Annals of Neurology, vol. 65, no. 3, pp. 326–336, 2009.

[15] J. Devulder, “Flupirtine in pain management: pharmacological properties and clinical use,” CNS Drugs, vol. 24, no. 10, pp. 867–881, 2010.

[16] S. Perovic, C. Schlegel, G. Pergande et al., “The triminopyridine flupirtine prevents cell death in rat cortical cells induced by N-Methyl-D-aspartate and gp120 of HIV-1,” European Journal of Pharmacology, vol. 288, no. 1, pp. 27–33, 1994.

[17] S. Perovic, G. Pergande, H. Ushijima, M. Kelve, J. Forrest, and W. E. G. Muller, “Flupirtine partially prevents neuronal injury induced by prion protein fragment and lead acetate,” Neurodegeneration, vol. 4, no. 4, pp. 369–374, 1995.

[18] K. Rupalla, W. Cao, and J. Krieglstein, “Flupirtine protects neurons against excitotoxic or ischemic damage and inhibits the increase in cytosolic Ca2+ concentration,” European Journal of Pharmacology, vol. 294, no. 2–3, pp. 469–473, 1995.

[19] F. Block, G. Pergande, and M. Schwarz, “Flupirtine reduces functional deficits and neuronal damage after global ischemia in rats,” Brain Research, vol. 754, no. 1-2, pp. 279–284, 1997.
[20] J. Seyfried, B. O. Evert, C. Rundfeldt et al., “Flupirtine and retigabine prevent L-glutamate toxicity in rat pheochromocytoma PC12 cells,” *European Journal of Pharmacology*, vol. 400, no. 2-3, pp. 155–166, 2000.

[21] I. Tsevi, R. Vicente, M. Grande et al., “KCNQ1/KCNE1 channels during germ-cell differentiation in the rat: expression associated with testis pathologies,” *Journal of Cellular Physiology*, vol. 202, no. 2-3, pp. 155–166, 2000.

[22] C. Lerche, C. R. Scherer, G. Seebohm et al., “Molecular cloning and functional expression of KCNQ5, a potassium channel subunit that may contribute to neuronal M-current diversity,” *Journal of Biological Chemistry*, vol. 275, no. 29, pp. 22395–22400, 2000.

[23] B. C. Schroeder, M. Hechenberger, F. Weinreich, C. Kubisch, and T. J. Jentsch, “KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents,” *Journal of Biological Chemistry*, vol. 275, no. 31, pp. 24089–24095, 2000.

[24] M. Roura-Ferrer, L. Solé, R. Martinez-Mármoil, N. Villalonga, and A. Felipe, “Skeletal muscle Kv7 (KCNQ) channels in myoblast differentiation and proliferation,” *Biochemical and Biophysical Research Communications*, vol. 351, no. 4, pp. 1043–1047, 2006.

[25] S. J. Wieland and Q. H. Gong, “Modulation of a potassium conductance in developing skeletal muscle,” *American Journal of Physiology*, vol. 268, no. 2, pp. C490–C495, 1995.

[26] T. J. Jentsch, M. Poët, J. C. Fuhrmann, and A. A. Zdebik, “Physiological functions of CLC Cl-channels gleaned from human genetic disease and mouse models,” *Annual Review of Physiology*, vol. 67, pp. 779–807, 2005.

[27] K. A. Kleopa and R. L. Barchi, “Genetic disorders of neuromuscular ion channels,” *Muscle and Nerve*, vol. 26, no. 3, pp. 299–325, 2002.

[28] M. Pusch, “Myotonia caused by mutations in the muscle chloride channel gene CLCN1,” *Human Mutation*, vol. 19, no. 4, pp. 423–434, 2002.

[29] M. J. Main, J. E. Cryan, J. R. B. Dupere, B. Cox, J. J. Clare, and S. A. Burbidge, “Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine,” *Molecular Pharmacology*, vol. 58, no. 2, pp. 253–262, 2000.